Patent Application
20220089635
Dexamethasone is a useful drug in a variety of medical fields, for example in the treatment of inflammatory diseases or conditions and in reducing inflammation associated with surgery or another therapy.
The disclosure features crystalline forms of Compound 1 (a dexamethasone prodrug dimer) and articles formed from the crystalline forms. The articles of the disclosure can be machined, molded, emulsion-processed, electrospun, electrosprayed, blow molded, or extruded to form a fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, microparticle (e.g., a microbead), nanoparticle (e.g., a nanobead), or any other type shaped article from which the dexamethasone prodrug dimer is released in a controlled fashion. Alternatively, the crystalline forms can be included in pharmaceutical compositions formulated for administration to a subject (e.g., oral dosage forms or injectable dosage forms).
In a first aspect, the invention features a solid crystalline form of Compound 1 (Form I) characterized by a powder X-ray diffraction (PXRD) diffractogram (Cu, λ=1.54060) including peaks expressed in degrees 2θ (±0.2°) at: 3.8°, 7.6°, and 12.1°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 8.7°, 9.7°, 10.6°, 13.3°, and 14.6°. In particular embodiments, the solid crystalline form has a melting point of 159±2.5° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form II) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 3.9°, 7.9°, 11.9°, and 15.8°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 4.8°, 5.7°, 6.6°, 8.6°, 9.7°, 13.4°, 14.5°, and 17.2°. In particular embodiments, the solid crystalline form has a melting point of 166±2.0° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form III) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 8.0°, 9.8°, 12.1°, and 13.8°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 3.9°, 15.0°, 16.1°, and 17.6°. In particular embodiments, the solid crystalline form has a melting point of 172±2.0° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form IV) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 8.9°, 11.4°, 14.1°, and 16.4°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 7.0°, 17.1°, 17.9°, 19.1°, 19.8°, and 20.3°. In particular embodiments, the solid crystalline form has a melting point of greater than 225° C., and a decomposition point of 225±2.0° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form V) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 5.6°, 6.5°, 8.1°, 12.7°, and 15.2°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 10.3°, 11.3°, 11.8°, 14.5°, and 17.3°. In particular embodiments, the solid crystalline form has a melting point of 206±4.0° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form VI) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 3.7°, 7.4°, and 16.7°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 9.9°, 11.1°, 13.2°, and 14.8°. In particular embodiments, the solid crystalline form has a melting point of 152±4.0° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form VII) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 3.5°, 7.6°, 9.6°, and 10.7°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 7.1°, 12.7°, 14.5°, and 15.2°. In particular embodiments, the solid crystalline form has a melting point of 152±3.0° C.
In another aspect, the invention features a solid crystalline form of Compound 1 (Form VIII) characterized by a powder X-ray diffraction (PXRD) diffractogram obtained using Cu(λ=1.54 Å) radiation including peaks expressed in degrees 2θ (±0.2°) at: 7.2°, 9.3°, 11.9°, 14.6°, and 17.0°. In particular embodiments, the solid crystalline form is further characterized by a PXRD diffractogram obtained using Cu(λ=1.54 Å) radiation including one, two, three, or more peaks expressed in degrees 2θ (±0.2°) at: 6.7°, 15.9°, 18.0°, and 18.6°.
In a related aspect, the invention features a pharmaceutical composition including a solid crystalline form of the invention and a pharmaceutically acceptable excipient. In particular embodiments, the pharmaceutical composition is formulated for oral administration, e.g., as a tablet or capsule. In other embodiments, the crystals are suspended in a solution for injection into a site on a subject (e.g., injection into a joint space). The pharmaceutically acceptable excipients used in the pharmaceutical composition can be any of those described herein.
The invention features a method for making an article including Compound 1, the method including (a) heating a solid crystalline form of the invention to form a melt; and (b) heat molding the melt to form the article.
The invention further features a method for making an article including Compound 1, the method including (a) heating a solid crystalline form of the invention to form a melt; and (b) injection molding the melt to form the article.
The invention features a method for making an article including Compound 1, the method including (a) heating a solid crystalline form of the invention to form a melt; and (b) blow molding the melt to form the article.
The invention further features a method for making an article including Compound 1, the method including (a) dissolving a solid crystalline form of the invention to form a solution; and (b) evaporating the solvent to form the article.
The invention features a method for making an article including Compound 1, the method including (a) dissolving a solid crystalline form of the invention to form a solution; and (b) electrospinning or electrospraying the solution to form the article.
The invention further features a method for making an article including Compound 1, the method including (a) heating a solid crystalline form of the invention to form a melt; and (b) electrospinning or electrospraying the melt to form the article.
The invention features a method for making an article including Compound 1, the method including (a) heating a solid crystalline form of the invention to form a melt; and (b) extruding the melt to form the article.
In some embodiments of the above methods, dexamethasone is released from the article through surface erosion.
In some embodiments of the above methods, the article releases less than 10% of dexamethasone, as a percentage of the total dexamethasone present in the article in prodrug form, at 37° C. in 100% bovine serum over 5 days; or the surface erosion releases less than 2% of dexamethasone, as a percentage of the total dexamethasone present in the article in prodrug form, at 37° C. in PBS over 5 days; or the surface erosion releases greater than 20% of dexamethasone, as a percentage of the total dexamethasone present in the article in prodrug form, at 37° C. in 100% bovine serum over not fewer than 6 days; or the surface erosion releases greater than 5.0% of dexamethasone as a percentage of the total dexamethasone present in the article in prodrug form, at 37° C. in PBS over not fewer than 6 days; or dexamethasone is released from the article at a rate such that t10 is greater than or equal to 1/10 of t50.
In some embodiments of the above methods, the article further includes from 0.1% to 10% (w/w) of one or more additives, wherein the one or more additives are selected from plasticizers, antioxidants, binders, lubricants, radio-opaque agents, and mixtures thereof.
In further embodiments of the above methods, the article is in the form of a coating, film, fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, hollow tube, microparticle, nanoparticle, or shaped article. In other embodiments, the article is free of controlled release excipient, free of a crystallization inhibiting excipient, free of a mechanical integrity enhancing excipient, and/or free of a binding excipient. In some embodiments, the article is in a glassy state.
In certain embodiments of the above methods, the controlled release is provided by any one of: dimensions of the article, composition of the article, crystallinity of the article, surface area of the article, or combinations thereof.
In some embodiments of the above methods, at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) (w/w) of the article is Compound 1.
In further embodiments of the above methods, Compound 1 or dexamethasone is released from the article through surface erosion. In some embodiments, the surface erosion releases less than 10% (e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%) of dexamethasone, as a percentage of the total drug, dexamethasone, present in the article in prodrug form, at 37° C. in 100% bovine serum over 5 days; or the surface erosion releases less than 2% (e.g., less than 1.8%, less than 1.5%, less than 1.2%, less than 1.0%, or less than 0.5%) of dexamethasone, as a percentage of the total drug, dexamethasone, present in the article in prodrug form, at 37° C. in PBS over 5 days. In still other embodiments of any of the above articles, the surface erosion releases greater than 20% (e.g., greater than 22%, 24%, 26%, 28%, or 30%) of dexamethasone (as a percentage of the total dexamethasone present in the article in prodrug form) at 37° C. in 100% bovine serum over not fewer than 6 days, 8 days, 10 days, or 12 days (e.g., greater than 24% of dexamethasone at 37° C. in 100% bovine serum over 10 days). In other embodiments of any of the above articles, the surface erosion releases greater than 5.0% (e.g., greater than 6.0%, 8.0%, 10%, 12%, or 15%) of dexamethasone (as a percentage of the total dexamethasone present in the article in prodrug form) at 37° C. in PBS over not fewer than 6 days, 8 days, 10 days, or 12 days (e.g., greater than 5% of dexamethasone at 37° C. in PBS over 10 days). The dexamethasone can be released from the article at a rate such that t10 is greater than or equal to 1/10 of t50. In some embodiments, the article further includes from 0.1% to 10% (e.g., from 0.1 to 5%, from 0.1 to 2%, from 0.5 to 2%, from 1 to 10%) (w/w) of one or more additives, wherein the one or more additives are selected from plasticizers, antioxidants, binders, lubricants, radio-opaque agents, and mixtures thereof.
In some embodiments of the above methods, the article is in the form of fibers having a mean diameter of from about 0.01 to 1 mm (e.g., 0.05 to 0.3 mm, 0.1 to 0.3 mm, 0.15 to 0.3 mm, 0.2 to 0.3 mm, 0.25 to 0.3 mm, 0.01 to 0.1 mm, 0.01 to 0.2 mm, 0.01 to 0.3 mm, 0.01 to 0.4 mm, 0.01 to 0.5 mm, 0.01 to 0.6 mm, 0.01 to 0.7 mm, 0.01 to 0.8 mm, or 0.01 to 0.9 mm). In other embodiments, the article is in the form of pellets having a mean diameter of from about 0.2 to 5 mm (e.g., from about 0.2 to 1 mm, from about 0.2 to 2 mm, from about 0.3 to 3 mm, from about 1.5 to 5 mm, from about 2 to 5 mm, from about 2.5 to 5 mm, from about 3 to 5 mm, from about 3.5 to 5 mm, from about 4 to 5 mm, or from about 4.5 to 5 mm). In further embodiments, the article is in the form of cylinders of from about 0.01 to 1 mm in diameter (e.g., about 0.01 to 0.2 mm, about 0.1 to 0.3 mm, about 0.1 to 0.4 mm, about 0.2 to 0.5 mm, about 0.1 to 0.6 mm, about 0.1 to 0.7 mm, about 0.1 to 0.8 mm, or about 0.1 to 0.9 mm) and 0.5 to 20 mm in length (e.g., about to 0.5 to 1 mm, about 0.5 to 2 mm, about 0.5 to 4 mm, about 0.5 to 6 mm, about 0.5 to 8 mm, about 0.5 to 10 mm, about 0.5 to 12 mm, about 0.5 to 14 mm, about 0.5 to 16 mm, or about 0.5 to 18 mm). In some embodiments, the length of the cylinder is about 0.5 to 10 mm, or about 1 to 10 mm. In other embodiments, the article is in the form of microparticles having a mean diameter of from about 1 to 1000 μm (e.g., about 10 to 1000 μm, about 100 to 1000 μm, about 200 to 1000 μm, about 500 to 1000 μm, about 700 to 1000 μm, or about 900 to 1000 μm). In still other embodiments, the article is in the form of nanoparticles having a mean diameter of from about 0.01 to 1 μm (about 0.05 to 1 μm, about 0.1 to 1 μm, about 0.2 to 1 μm, about 0.3 to 1 μm, about 0.4 to 1 μm, about 0.5 to 1 μm, about 0.6 to 1 μm, about 0.7 to 1 μm, about 0.8 to 1 μm, or about 0.9 to 1 μm).
In some embodiments of the above methods, the article is a coating that resides on the surface of an implantable medical device. In further embodiments of the above methods, the coating has a glassy state and is formed from a crystal form of the disclosure.
The crystal forms of the invention can be useful as starting materials in the manufacture of articles. The articles can be formed by a process including the steps of: (a) heating the crystal form to form a melt; (b) cooling the melt to form a glassy state composition; and (c) heating the glassy state composition to a temperature above the glass transition temperature of the glassy state composition and shaping the glassy state composition to form a shaped article. Step (c) can include extruding, molding, blow molding, heat spinning, electrospinning, or electrospraying the glassy state composition to form the shaped article. In some embodiments, the method forms an article free of controlled release polymer, free of a crystallization inhibiting excipient, free of a mechanical integrity enhancing excipient, and/or free of a binding excipient; or the method forms an article that optionally has a glassy state. In further embodiments of the methods, the article is in the form of a coating, film, fiber, fiber mesh, woven fabric, non-woven fabric, pellet, cylinder, hollow tube, microparticle, nanoparticle, or shaped article.
In another embodiment of any of the above methods, the article includes a solid crystalline form of the invention. In particular embodiments, the article is a microparticle or nanoparticle.
In a related aspect, the invention features a method of treating a subject suffering from an inflammatory condition, the method comprising administering to the subject a composition comprising the solid crystalline form of the invention. The inflammatory condition is osteoarthritis, or any other inflammatory condition described herein. In particular embodiments, the administering is by intraarticular injection.
In a related aspect, the invention features a microparticle or nanoparticle including a solid crystalline form of the invention. In particular embodiments, the microparticle or nanoparticle is formulated for oral administration, e.g., as a tablet or capsule containing the microparticles or nanoparticles. In other embodiments, the microparticles or nanoparticles are suspended in a solution for injection into a site on a subject (e.g., injection into a joint space).
The term “Compound 1,” as used herein, refers to the compound depicted below in Formula (I):
The term “free of controlled release polymer,” as used herein, refers to the absence of an amount of a polymeric material of greater than 10 KDa in the articles produced by the methods of the disclosure that is sufficient to delay or slow the release of the dexamethasone prodrug dimer from the article in comparison to the release profile observed for an otherwise identical article containing none of the polymeric material, where the release profile is measured at 37° C. in 100% fetal bovine serum (FBS). The term “free of a crystallization inhibiting excipient,” as used herein, refers to the absence of an amount of an excipient in the articles produced by the methods of the disclosure that is sufficient to reduce the amount of crystalline dexamethasone prodrug dimer in the article in comparison to the amount of crystalline dexamethasone prodrug dimer observed in an otherwise identical article containing none of the excipient. The level of crystallinity can be measured using DSC or XRD. In particular embodiments, the articles of the disclosure are free of a crystallization inhibiting excipient that is a polymeric material of greater than 10 KDa.
The term “free of a mechanical integrity enhancing excipient,” as used herein, refers to the absence of an amount of an excipient in the articles produced by the methods of the disclosure that is sufficient to increase the mechanical integrity of the article in comparison to the mechanical integrity of an otherwise identical article containing none of the excipient. The mechanical integrity of an article can be tested using a 3- or 4-point mechanical bend test (ASTM C1684-18) on the formulation with or without the excipient with the article in the shape of a rod either in the dry state (prior to drug release), wet state (prior to drug release), or in the wet state after 15-30% drug release. For articles with a rectangular shape, the mechanical integrity can be tested using a 3-point mechanical bend test (ASTM D790-17) or 4-point mechanical bend test (ASTM D6272) on the formulation with or without excipient either in the dry state (prior to drug release), wet state (prior to drug release), or in the wet state after 15-30% drug release. A reduction in mechanical integrity causes the articles to break apart sooner, increasing the total surface area of the quantity of articles, and resulting in a more rapid release profile. In particular embodiments, the articles of the disclosure are free of a mechanical integrity enhancing excipient that is a polymeric material of greater than 10 KDa.
The term “free of a binding excipient,” as used herein, refers to the absence of an amount of an excipient in the articles produced by the methods of the disclosure that is sufficient to delay or slow the release of the dexamethasone prodrug dimer from the article in comparison to the release profile observed for an otherwise identical article containing none of the binding excipient, where the release profile is measured at 37° C. in 100% FBS.
The term “cylinder,” as used herein, refers to the shape of the pharmaceutical compositions of the disclosure that has parallel sides and a circular or oval cross section, or a shaped cross section (e.g., a star shaped cross section). A mean diameter of the cylinder can range from about 0.01 to 1 mm diameter, e.g., about 0.01 to 0.2 mm, about 0.1 to 0.3 mm, about 0.1 to 0.4 mm, about 0.2 to 0.5 mm, about 0.1 to 0.6 mm, about 0.1 to 0.7 mm, about 0.1 to 0.8 mm, or about 0.1 to 0.9 mm. A mean length of the cylinder can range from about 0.05 to 20 mm, e.g., about 0.05 to 1 mm, about 0.5 to 2 mm, about 0.5 to 4 mm, about 0.5 to 6 mm, about 0.5 to 8 mm, about 0.5 to 10 mm, about 0.5 to 12 mm, about 0.5 to 14 mm, about 0.5 to 16 mm, or about 0.5 to 18 mm. In some embodiments, the mean diameter of the cylinder is in the range of about 0.01 to 1 mm and the mean length of the cylinder is about 0.1 mm to 4.0 mm. In some embodiments, the mean length of the cylinder is about 0.5 to 10 mm, or about 1 to 10 mm.
The term “fiber,” as used herein, refers to the shape of the pharmaceutical compositions of the disclosure that is elongated or threadlike. A mean diameter of the fiber can range from about 0.01 to 1 mm, e.g., 0.05 to 0.3 mm, 0.1 to 0.3 mm, 0.15 to 0.3 mm, 0.2 to 0.3 mm, 0.25 to 0.3 mm, 0.01 to 0.1 mm, 0.01 to 0.2 mm, 0.01 to 0.3 mm, 0.01 to 0.4 mm, 0.01 to 0.5 mm, 0.01 to 0.6 mm, 0.01 to 0.7 mm, 0.01 to 0.8 mm, or 0.01 to 0.9 mm. A mean length of the fiber can range from about 20 to 20,000 mm, e.g., about 20 to 1000 mm, about 20 to 2,000 mm, about 100 to 2,000 mm, about 100 to 5,000 mm, about 1,000 to 8,000 mm, about 2,000 to 8,000 mm, about 2,000 to 10,000 mm, about 2,000 to 12,000 mm, about 2,000 to 15,000 mm, or about 5,000 to 18,000 mm.
The term “fiber mesh,” as used herein refers to a web or a net in having many attached or woven fibers. The fiber mesh can have aligned and unaligned morphologies.
The term “glassy state,” as used herein, refers to an amorphous solid including greater than 70%, 80%, 90%, 95%, 98%, or 99% (w/w) of Compound 1 and exhibiting a glass transition temperature above 38° C. In the glassy state, as measured by DSC or XRD, the level of crystallinity is low, ranging from 0-15%, e.g., 0-1%, 0-3%, 0-5%, 0-7%, 0-9%, 0-10%, or 0-13%. Glass formulations of the disclosure can be formed using heat processing or solvent processing one or more crystal forms of the invention.
The term “microparticle,” as used herein, refers to the shape of the pharmaceutical compositions of the disclosure, which can be regularly or irregularly shaped. A mean diameter of the microparticle can range from about 1 to 1000 μm, e.g., about 10 to 1000 μm, about 100 to 1000 μm, about 200 to 1000 μm, about 500 to 1000 μm, about 700 to 1000 μm, or about 900 to 1000 μm. As used herein, a microbead is a microparticle that is spherical.
The term “nanoparticle,” as used herein, refers to the shape of the pharmaceutical compositions of the disclosure, which can be regularly or irregularly shaped. A mean diameter of the nanoparticle can range from about 0.01 to 1 μm, e.g., about 0.05 to 1 μm, about 0.1 to 1 μm, about 0.2 to 1 μm, about 0.3 to 1 μm, about 0.4 to 1 μm, about 0.5 to 1 μm, about 0.6 to 1 μm, about 0.7 to 1 μm, about 0.8 to 1 μm, or about 0.9 to 1 μm. As used herein, a “nanobead” refers to a nanoparticle that is spherical.
The term “non-woven fabric,” as used herein, refers to a web structure bonded together by entangling fibers.
The term “pellet,” as used herein, refers to the shape of the pharmaceutical compositions of the disclosure that is rounded, spherical, or cylindrical, or a combination thereof. A mean diameter of the pellet can range from about 0.2 to 5 mm, e.g., from about 0.2 to 1 mm, from about 0.2 to 2 mm, from about 0.3 to 3 mm, from about 1.5 to 5 mm, from about 2 to 5 mm, from about 2.5 to 5 mm, from about 3 to 5 mm, from about 3.5 to 5 mm, from about 4 to 5 mm, or from about 4.5 to 5 mm.
The term “surface erosion,” as used herein refers to a process of a gradual disintegration of the pharmaceutical compositions of the disclosure and release of a free drug from the dexamethasone prodrug dimer. Surface erosion can be tailored to achieve desired drug release rates. The rate of surface erosion and release of a given drug from a dexamethasone prodrug dimer may also depend on the quantity of the loaded dexamethasone prodrug dimer as a percent of the final dexamethasone prodrug dimer formulation, article size, solubility of dexamethasone prodrug dimer (e.g., through selection of appropriate linker), and/or surface area of the article. For example, surface erosion mechanism of drug release allows drug delivery articles to be tailored with specific physical features (dimensions, diameters, surface areas, total mass, etc.) to achieve desired drug release rates, and drug release may be designed to be initiated within minutes or hours, and may continue to occur over days, weeks, months, or years.
As used herein, “t50” is the time at which 50% of the releasable drug has been released from an article of the disclosure. Time t10 is, correspondingly, the time at which 10% of the releasable drug has been released from an article of the disclosure. When the release curve is perfectly linear, t10=1/5 of t50. When there is an initial burst of released drug, t10 is much less than ⅕ of t50. In the compositions and methods of the disclosure t10 can be equal to or greater than 1/10 of t50. Drug release from an article or compound of the disclosure can be measured at 37° C. in 100% bovine serum, or at 37° C. in PBS, as described in Example 1.
The term “woven fabric,” as used herein, refers to pharmaceutical compositions that resemble materials that are formed by weaving of fibers.
While the clinical importance of sustained drug release delivery systems to maintain therapeutic concentration of drugs for extended periods of time (e.g., days to weeks, to months or even years) has been well acknowledged for decades, there has been a limited number of successfully commercialized products on the market to date. It is recognized in this disclosure that to develop successful sustained drug delivery systems, technical difficulties must be overcome ranging from drug degradation during formulation process; lack of controlled release, including unwanted burst or incomplete release associated with diffusion or bulk erosion mechanisms of drug release; low encapsulation efficiency; and formulation complexity.
For locally administered sustained release delivery systems, it is recognized in this disclosure that additional challenges can arise where the mass balance of the carrier or matrix for the drug hinders drug loading, or where the carriers and matrices produce unwanted effects (i.e., such as local inflammation). It is recognized in this disclosure that there is an unmet need for a sustained release drug system that is formulated to release dexamethasone via a surface erosion process in the absence or with a minimal amount of carrier and/or excipient agents, at a rate-controlled manner over an extended period of time (e.g., days to weeks, to months or even years), where the system contains predominantly dexamethasone prodrug and minimizes side effects associated with the use of carriers or matrices.
This disclosure describes crystal forms of a dexamethasone prodrug dimer that can be used to form pharmaceutical compositions that are produced from viscous fluids, such as a melt or solution, in order yield shaped articles where most of the material is in a glassy state. The shaped articles can have the ability to release their prodrug/drug elements from these shaped forms upon surface mediated degradation/dissolution. This can provide a controlled rate of drug release over days, weeks, months, or years, due to unique interactions between the molecules that exist in a mostly amorphous state while holding the shaped form intact as the surface erodes. Articles formed from the crystal forms of the disclosure can yield sustained and uniform release of the dexamethasone prodrugs, without exhibiting any burst release (e.g., t10 can be equal to or greater than 1/10 of t50) and without reliance upon degradable matrices, which can cause undesirable local side effects (such as inflammation). The high drug loading that can be present in the articles of the disclosure are suitable for producing locally effective concentrations of a dexamethasone for periods of days to weeks to months or even years.
Alternatively, the crystal forms of the disclosure can be incorporated into pharmaceutical compositions for administration to a subject (e.g., for the treatment of inflammation).
The advantages associated with the use of the crystal forms of the invention can include: (i) increased storage stability that can produce longer drug substance shelf life; (ii) increased thermal stability to permit high temperature processing with little or no discernable degradation; (iii) modified release profiles for scenarios where the crystal form is present in the final drug product as administered; (iv) decreased melting point to allow thermal processing at lower temperatures; (v) increased solubility in a preferred solvent (e.g. class 3 solvents, low boiling point solvent to get low residual solvent in final product); (vi) decreased hygroscopicity; (vii) ease of manufacturing/generating crystals/particles in the appropriate size for retention in local tissue; and (viii) sufficient mechanical properties allowing resuspension and administration without altering crystal/particle size.
Crystalline Formulations
The pharmaceutical compositions of the invention including a crystalline form of Compound 1 can include a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Some examples of materials which can serve as pharmaceutically acceptable excipients include, but are not limited to, sugars such as lactose, glucose, mannitol, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; natural and synthetic phospholipids, such as soybean and egg yolk phosphatides, lecithin, hydrogenated soy lecithin, dimyristoyl lecithin, dipalmitoyl lecithin, distearoyl lecithin, dioleoyl lecithin, hydroxylated lecithin, lysophosphatidylcholine, cardiolipin, sphingomyelin, phosphatidylcholine, phosphatidyl ethanolamine, diastearoyl phosphatidylethanolamine (DSPE) and its pegylated esters, such as DSPE-PEG750 and, DSPE-PEG2000, phosphatidic acid, phosphatidyl glycerol and phosphatidyl serine. Commercial grades of lecithin which are preferred include those which are available under the trade name Phosal® or Phospholipon® and include Phosal 53 MCT, Phosal 50 PG, Phosal 75 SA, Phospholipon 90H, Phospholipon 90G and Phospholipon 90 NG; soy-phosphatidylcholine (SoyPC) and DSPE-PEG2000 are particularly preferred; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Non-limiting examples of binding agents that may be used in pharmaceutical compositions of the present invention include but are not limited to hydroxyalkyl cellulose, a hydroxyalkylalkyl cellulose, hydroxypropyl methyl cellulose, or a polyvinylpyrrolidone.
Non-limiting examples of osmotic agents that may be used in pharmaceutical compositions of the present invention include, but are not limited to, sorbitol, mannitol, sodium chloride, or other salts. Non-limiting examples of biocompatible polymers employed in the contemplated dosage forms include but are not limited to poly(hydroxy acids), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, poly(vinyl alcohols), poly (vinyl acetate), polystyrene, polyurethanes and co-polymers thereof, synthetic celluloses, polyacrylic acids, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone), ethylene vinyl acetate, copolymers and blends thereof.
Non-limiting examples of hygroscopic polymers that may be employed in the contemplated dosage forms include, but are not limited to, polyethylene oxide (e.g., Polyox® with MWs from 4,000,000 to 10,000,000), cellulose, hydroxymethylcellulose, hydroxyethylcellulose, crosslinked polyacrylic acids, and xanthan gum.
Non-limiting examples of rate-controlling polymers the may be employed in the contemplated dosage forms include but are not limited to polymeric acrylate, methacrylate lacquer or mixtures thereof, polymeric acrylate lacquer, methacrylate lacquer, an acrylic resin including a copolymer of acrylic and methacrylic acid esters, or an ammonium methacrylate lacquer with a plasticizer.
The above-described compositions, in any of the forms described herein, can be used for treating disease (e.g., inflammatory disease, or any other disease or condition described herein). An effective amount refers to the amount of an active compound/agent that is required to confer a therapeutic effect on a treated subject. Effective doses will vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
A pharmaceutical composition of this invention can be administered by any suitable route, e.g., parenterally, orally, nasally, rectally, topically, buccally, by ophthalmic administration, or by inhalation. The term “parenteral” as used herein refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection.
A sterile injectable composition can be a suspension in a non-toxic parenterally acceptable diluent or solvent. Such diluents include, but are not limited to, 1,3-butanediol, mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides). Fatty acids, such as, but not limited to, oleic acid and its glyceride derivatives, are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as, but not limited to, olive oil or castor oil, or polyoxyethylated versions thereof. These oil solutions or suspensions also can contain a long chain alcohol diluent or dispersant such as, but not limited to, carboxymethyl cellulose, or similar dispersing agents. Other commonly used surfactants, such as, but not limited to, Tweens or Spans or other similar emulsifying agents or bioavailability enhancers, which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms also can be used for the purpose of formulation.
A composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions. In some embodiments, the dosage form is an oral dosage form such as a pressed tablet, hard or soft gel capsule, enteric coated tablet, osmotic release capsule, or unique combination of excipients. In the case of tablets, commonly used excipients include, but are not limited to, lactose, mannitol, and corn starch. Lubricating agents, such as, but not limited to, magnesium stearate, also are typically added. For oral administration in a capsule form, useful diluents include, but are not limited to, lactose, mannitol, glucose, sucrose, corn starch, potato starch, or cellulose. In additional embodiments, the dosage form includes a capsule wherein the capsule contains a mixture of materials to provide a desired sustained release formulation. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
Pharmaceutical compositions for topical administration according to the described invention can be formulated as solutions, ointments, creams, suspensions, lotions, powders, pastes, gels, sprays, aerosols, or oils. Alternatively, topical formulations can be in the form of patches or dressings impregnated with active ingredient(s), which can optionally include one or more excipients or diluents. In some preferred embodiments, the topical formulations include a material that would enhance absorption or penetration of the Compound 1 through the skin or other affected areas.
A topical composition contains a safe and effective amount of a dermatologically acceptable excipient suitable for application to the skin. A “cosmetically acceptable” or “dermatologically-acceptable” composition or component refers a composition or component that is suitable for use in contact with human skin without undue toxicity, incompatibility, instability, or allergic response. The excipient enables an active agent and optional component to be delivered to the skin at an appropriate concentration(s). The excipient thus can act as a diluent, dispersant, solvent, or the like to ensure that the active materials are applied to and distributed evenly over the selected target at an appropriate concentration. The excipient can be solid, semi-solid, or liquid. The excipient can be in the form of a lotion, a cream, or a gel, in particular one that has a sufficient thickness or yield point to prevent the active materials from sedimenting. The excipient can be inert or possess dermatological benefits. It also should be physically and chemically compatible with the active components described herein, and should not unduly impair stability, efficacy, or other use benefits associated with the composition.
Article Formulations
The pharmaceutical compositions of the disclosure can include an article in the form of fibers, fiber meshes, woven fabrics, non-woven fabrics, pellets, cylinders, hollow tubes, microparticles (e.g., microbeads), nanoparticle (e.g., nanobeads), or other shaped articles. In some embodiments, the pharmaceutical composition of the disclosure has a non-circular shape that affects, e.g., increases, the surface area (e.g., extruded through star-shaped dye). Suitable pharmaceutical compositions for use with this disclosure can be small regularly or irregularly shaped particles, which can be solid, porous, or hollow.
Different forms of pharmaceutical compositions of the present disclosure (e.g., fibers, fiber meshes, woven fabrics, non-woven fabrics, pellets, cylinders, hollow tubes, microparticles (e.g., microbeads), nanoparticles (e.g., nanobeads), or other shaped articles) can have the advantages of providing a controllable surface area, being easily injected, not requiring removal after completion of drug release, and allow for tailoring drug release rates required for a given indication. When used as an injectable drug delivery device, drug release rate and interaction with cells are strongly dependent on the size distribution of the pharmaceutical composition form.
Article Processing Methods
Articles of the disclosure can be formed using any number of the methods, for example, heat processing or solvent processing of the crystal forms of the dexamethasone prodrug dimer Compound 1. Heat processing can include heat molding, injection molding, extrusion, 3D printing, melt electrospinning, fiber spinning, fiber extrusion, and/or blow molding. Solvent processing may include coating, micro printing, emulsion processing dot printing, micropatterning, fiber spinning, solvent blow molding, electrospraying, and electrospinning.
Electrospraying Method
In some embodiments, the crystal forms of the disclosure are dissolved in a solvent (e.g., acetone) at concentrations ranging from, e.g., 10-30% w/v, and are electrosprayed to form micro- and nanobeads. The solutions can be loaded into a syringe and can be injected at a particular rate, e.g., 0.5 mL/h, onto a stationary collection plate. Between the needle and collecting surface, a potential difference of, e.g., 18 kV, can be maintained. Exemplary concentration of 10% w/v is used to obtain nanoparticles. In other embodiments, a concentration of 30% w/v is used to obtain microbeads.
Fiber Spinning Methods
In some embodiments, the pharmaceutical compositions of the disclosure, e.g., fibrous meshes with aligned and unaligned morphologies are prepared by electrospinning. The crystal forms of the disclosure are dissolved in a solvent (e.g., THF, or 1:1 ratio of DCM/THF). The solutions may be injected from a syringe at a particular rate, e.g., 0.5 mL/h, onto a cylindrical mandrel rotating at a particular rotational speed, e.g., 1150 rpm, to obtain aligned fibers, or onto a stationary collector surface to obtain unaligned fibers. A potential difference (e.g., 18 kV or 17 kV) can be maintained between the needle and collecting surface for aligned and random fibers.
In other embodiments, fibers are prepared either from the melt at elevated temperatures, the glassy state intermediate, or from solution by dissolving the pharmaceutical compositions of the disclosure in a solvent (e.g., DCM, THF, or chloroform). As used herein, melt spinning describes heat processing from the melt state, heat spinning describes heat processing from the glassy state, and wet, dry, and gel spinning describe solution processing.
The viscous melt, intermediate, or solution can be fed through a spinneret and fibers may be formed upon cooling (melt or heat spinning) or following solvent evaporation with warm air as the Compound 1 exits the spinneret (dry spinning). Wet spinning and gel spinning, performed according to methods known in the art, may also be used to produce the fibers of the disclosure. Heat spinning describes a process that is essentially the same as the melt spinning process, but performed with the glassy state intermediate and heated above the glass transition temperature (Tg) to get the viscous fluid to extrude/spin instead of the melt. Alternatively, tweezers may be dipped into melted material or concentrated solutions and retracted slowly in order to pull fibers. The rate of pulling and distance pulled may be varied to yield fibers and columnar structures of different thickness.
Emulsion Method
In some embodiments, micro-particles or nano-particles made from the crystal forms can be formed using an emulsion process. The crystal form can be dissolved in an organic solvent (e.g., DCM, THF, etc.) and a surfactant (e.g., SDS, PVA, etc.) may be added to the solution/mixture at a low percentage (e.g., 1%). The resulting mixture may be stirred for the appropriate time at room temperature to form an emulsion. The emulsion may be subsequently added to Milli-Q water under stirring for an appropriate time (e.g., 1 h) to remove residual solvent. The resulting micro- or nano-particles may be collected by centrifugation and dried to obtain the desired form.
Extrusion Method
In some embodiments, injectable cylinders made from the crystal forms may be formed by heat extrusion. The crystal form can be loaded into a hot melt extruder, heated to a temperature above the melting point (for crystalline compositions) or glass transition temperature (for pre-melted or amorphous compositions), and extruded using a light compressive force to push the material through the nozzle and a light tensile force to pull the material out of the extruder. The extrudate may be cut to the desired length for appropriate drug dosing for the indication of interest.
Bead Sizing and Milling
In some embodiments, a milling process may be used to reduce the size of an article of the disclosure to form sized particles, e.g., beads, in the micrometer (microbeads) to nanometer size range (nanobeads). The milling process may be performed using a mill or other suitable apparatus. Dry and wet milling processes such as jet milling, cryo-milling, ball milling, media milling, sonication, and homogenization are known and can be used in methods described herein. Generally, in a wet milling process, a suspension of the material to be used as the core is agitated with or without excipients to reduce particle size. Dry milling is a process wherein the material to be used as the article core is mixed with milling media with or without excipients to reduce particle size. In a cyro-milling process, a suspension of the material to be used as the core is mixed with milling media with or without excipients under cooled temperatures. In some embodiments, subsequent heating of the milled microparticle above the Tg is needed to achieve a spherical shape, or particles with non-spherical shapes can be used as milled.
Low Temperature Processing Using Intermediate Glassy State Articles
In certain embodiments, the dexamethasone prodrug dimer has a limited window (e.g., short timeframe of seconds to minutes) of thermal stability, whereby the purity of the dimer is minimally affected at elevated temperatures. In some embodiments, it is beneficial to make an intermediate glassy state form (e.g., film, pellet, micro-particles, or other shaped article). This can be accomplished by heat or solvent processing to remove or reduce the crystallinity of the material to form a glassy state composition. The glassy state composition is subsequently heat processed ata lower temperature (e.g., processing just above the glass transition temperature (Tg), and below the melt temperature (Tm)). This can provide a longer timeframe for heat processing the glassy state material into the final shaped article, while reducing the impact of processing conditions on the purity of the dexamethasone prodrug dimer in the article.
Exemplary processing details are provided in the Examples.
Powder X-Ray Diffraction (PXRD) Methods
Depending on the method in which the embodiments of the invention are prepared, the methodology and instrument used for PXRD analysis, and the scale selected to display results, the intensity of a given peak observed in the PXRD diffractogram may vary when compared to the same peak in the representative PXRD diffractograms provided in
In addition to the differences in relative peak intensities that may be observed in comparison to the representative PXRD diffractograms provided in
Further, it is understood that, depending on the instrument used for X-ray analysis and its calibration, uniform offsets in the peak position of each peak in a PXRD diffractogram of greater than 0.2° 2θ may be observed when compared to the representative PXRD diffractograms provided in
As used herein, the term ‘crystalline form’ refers to a substance with a particular arrangement of molecular components in its crystal lattice, and which may be identified by physical characterization methods such as PXRD. As used herein, the term crystalline form is intended to include single-component and multiple-component crystalline forms of Compound 1. Single-component forms of Compound 1 consist solely of Compound 1 in the repeating unit of the crystal lattice. Multiple-component forms of Compound 1 include solvates of Compound 1 wherein a solvent is also incorporated into the crystal lattice.
Drug Delivery
The pharmaceutical compositions of the disclosure provide optimal delivery of dexamethasone as they release the dexamethasone from an article of the disclosure in a controlled manner, for example, by surface erosion. The surface erosion mechanism of drug release may allow the shaped article to maintain its physical form (e.g. shape/geometry of the article), while gradually decreasing in size as the surface erodes (e.g., like a bar of soap), rather than bulk erosion that is characteristic of some polymer-based drug release vehicles (e.g. polylactic/glycolic acid). This may inhibit burst release and reduce the formation of inflammatory particulates. The drug can be controlled to be delivered over a desired period of time. A slower and steadier rate of delivery may in turn result in a reduction in the frequency with which the pharmaceutical composition must be administered to a subject, and improve the safety profile of the drug. Drug release can also be tailored to avoid side effects of slower and longer release of the drug by engineering the article to provide steady release over a comparatively shorter period of time.
The rate of release of a given drug from the pharmaceutical composition may also depend on the quantity of the loaded drug dimer as a percent of the final drug dimer formulation, e.g., by using a pharmaceutical excipient that acts as a bulking agent. Another factor that can affect the release rate of a drug from, for example a microbead, is the microbead size. In some embodiments, drug release is affected by changes in surface area of the formulation, e.g., by changing the diameter of the microbeads. By adjusting the vide supra factors, dissolution, degradation, diffusion, and controlled release may be varied over wide ranges. For example, release may be designed to be initiated over minutes to hours, and may extend over the course of days, weeks, months, or years.
Uses and Pharmaceutical Compositions
In some embodiments, the crystal forms of the disclosure are used to prepare a drug delivery device (or, e.g., a drug depot) with a minimal need for additives. This may achieve a local, sustained release and a local biological effect, while minimizing a systemic response. In some embodiments, when present, the additives are in small amounts and do not affect the physical or bulk properties. In some embodiments, when present, the additives do not alter the drug release properties from the pharmaceutical composition but rather act to improve processing of the prodrug dimer into the shaped article. In some embodiments, the pharmaceutical compositions contain additives such as a plasticizer (e.g., to reduce thermal transition temperatures), an antioxidant (e.g., to increase stability during heat processing), a binder (e.g., to add flexibility to the fibers), a bulking agent (e.g., to reduce total drug content), a lubricant, a radio-opaque agent, or mixtures thereof. The additives may be present at 30% (w/w), e.g., 20% (w/w), 10% (w/w), 7% (w/w), 5% (w/w), 3% (w/w), 1% (w/w), 0.5% (w/w), or 0.1% (w/w). Examples of plasticizers are polyols, e.g., glycerol, ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, propylene glycol, triacetin, sorbitol, mannitol, xylitol, fatty acids, monosaccharides (e.g., glucose, mannose, fructose, sucrose), ethanolamine, urea, triethanolamine, vegetable oils, lecithin, or waxes. Exemplary antioxidants are glutathione, ascorbic acid, cysteine, or tocopherol. The binders and bulking agents can be, e.g., polywinylpyrrolidone (PVP), starch paste, pregelatinized starch, hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC), or polyethylene glycol (PEG) 6000.
Methods involving treating a subject may include preventing a disease, disorder or condition from occurring in the subject which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected (e.g., such treating the pain of a subject by administration of an agent even though such agent does not treat the cause of the pain).
Pharmaceutical compositions containing Compound 1 described herein may be administered to a subject via any route known in the art. These include, but are not limited to, oral, sublingual, nasal, intradermal, subcutaneous, intramuscular, rectal, vaginal, intravenous, intraarterial, intracisternally, intraperitoneal, intravitreal, periocular, topical (as by powders, creams, ointments, or drops), buccal and inhalational administration. Desirably, the articles of the disclosure are administered parenterally as injections (intravenous, intramuscular, or subcutaneous), or locally as injections (intraocularly or into a joint space). The formulations are admixed under sterile conditions with a pharmaceutically acceptable carrier or suspension or resuspension agents (e.g., for micro- and nanoparticles) and any needed preservatives or buffers as may be required.
The articles of the disclosure described herein including a dexamethasone prodrug dimer may be administered to a subject to be delivered in an amount sufficient to deliver to a subject a therapeutically effective amount of an incorporated pharmaceutical agent as part of prophylactic or therapeutic treatment, or as a part of adjunctive therapy to avoid side-effects of another drug or therapy. In general, an effective amount of a pharmaceutical agent or component refers to the amount necessary to elicit the desired biological response. The desired concentration of pharmaceutical agent in the article of the disclosure will depend on numerous factors, including, but not limited to, absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the dexamethasone dimer from the subject compositions, the desired biological endpoint, the agent to be delivered, the target tissue, etc. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.
The concentration and/or amount of any pharmaceutical agent to be administered to a subject may be readily determined by one of ordinary skill in the art. Known methods are also available to assay local tissue concentrations, diffusion rates from pharmaceutical compositions and local blood flow before and after administration of the therapeutic formulation.
Sterilization of Formulations
Generally, it is desired that a formulation is sterile before or upon administration to a subject. A sterile formulation is essentially free of pathogenic microorganisms, such as bacteria, microbes, fungi, viruses, spores, yeasts, molds, and others generally associated with infections. In some embodiments, articles of the disclosure may be subject to an aseptic process and/or other sterilization process. An aseptic process typically involves sterilizing the components of a formulation, final formulation, and/or container closure of a drug product through a process such as heat, gamma irradiation, ethylene oxide, or filtration and then combining in a sterile environment. In some cases, an aseptic process is preferred. In other embodiments, terminal sterilization is preferred.
Treatment Methods
The formulations of the disclosure may be used in the fields of ophthalmology, oncology, laryngology, endocrinology and metabolic diseases, rheumatology, urology, neurology, cardiology, dental medicine, dermatology, otology, post-surgical medicine, and orthopedics.
Ophthalmic Uses
In certain embodiments, the articles of the disclosure may be used prevent, treat or manage diseases or conditions at the back of the eye, such as at the retina, macula, choroid, sclera and/or uvea.
In some embodiments, the articles of the disclosure are used as injectable drug delivery devices for ophthalmology (e.g., intravitreal injection, coating on a minimally invasive glaucoma surgery (MIGS) devices, or implant in blebs). During an intravitreal injection a medication is placed directly into the space in the back of the eye called the vitreous cavity, which is filled with a jelly-like fluid called the vitreous humor gel. Intravitreal injections may be used to treat retinal diseases such as diabetic retinopathy, macular degeneration, macular edema, uveitis, and retinal vein occlusion.
In certain embodiments, the articles of the disclosure may be used to treat, prevent, or manage an ocular condition, i.e., a disease, ailment, or condition that affects or involves the eye or one or more of the parts or regions of the eye. In some embodiments, the articles of the disclosure may be used to treat, prevent, or manage an ocular condition at the front of the eye of a subject. A front of the eye ocular condition includes a disease, ailment or condition, such as for example, post-surgical inflammation; uveitis; infections; aphakia; pseudophakia; astigmatism; blepharospasm; cataract; conjunctival diseases; conjunctivitis; corneal diseases; corneal ulcer; dry eye syndromes; eyelid diseases; lacrimal apparatus diseases; lacrimal duct obstruction; myopia; presbyopia; pupil disorders; corneal neovascularization; refractive disorders and strabismus. In some embodiments, articles of the disclosure may be used to treat, prevent, or manage an ocular condition at the back of the eye of a subject. A posterior ocular condition can include a disease, ailment, or condition, such as intraocular melanoma; acute macular neuroretinopathy; Behcet's disease; choroidal neovascularization; uveitis; diabetic uveitis; histoplasmosis; infections, such as fungal or viral-caused infections; macular degeneration, such as acute macular degeneration, non-exudative age related macular degeneration and exudative age related macular degeneration; edema, such as macular edema (e.g., cystoid macular edema (CME) and diabetic macular edema (DME)); multifocal choroiditis; ocular trauma which affects a posterior ocular site or location; ocular tumors; retinal disorders, such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic retinopathy), proliferative vitreoretinopathy (PVR), retinal arterial occlusive disease, retinal detachment, uveitic retinal disease; sympathetic opthalmia; Vogt Koyanagi-Harada (VKH) syndrome; uveal diffusion; a posterior ocular condition caused by or influenced by an ocular laser treatment; posterior ocular conditions caused by or influenced by a photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membrane disorders, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction, retinitis pigmentosa, retinoblastoma, and glaucoma. In some embodiments, the articles of the disclosure may be used to treat, prevent, or manage dry eye in a subject. In some embodiments, the articles of the disclosure may be used to treat, prevent, or manage inflammation in the eye of a subject. Inflammation is associated with a variety of ocular disorders. Inflammation may also result from a number of ophthalmic surgical procedures, including cataract surgery. In some embodiments, the pharmaceutical agent that is delivered into the eye by the articles of the disclosure and/or methods described herein may be a corticosteroid. In some embodiments, the pharmaceutical compositions of the disclosure are used as adjunctive therapy to reduce inflammation and fibrosis associated with devices (e.g., minimally invasive glaucoma surgery (MIGS) devices). In some embodiments, articles of the disclosure may be used to treat, prevent, or manage age-related macular degeneration (AMD) in a subject.
Osteoarthritis Treatment
In some embodiments, the articles of the disclosure are used for the treatment of osteoarthritis (OA). For OA of the knee, intraarticular (IA) injection (e.g., steroids) is preferred as the last non-operative modality, if other conservative treatment modalities are ineffective. Steroids may be used to reduce inflammation in tendons and ligaments in osteoarthritic joints. IA steroid injections provide short term reduction in OA pain and can be considered as an adjunct to core treatment for the relief of moderate to severe pain in people with OA. Dexamethasone can be used in the treatment of OA. In some embodiments, microspheres of the disclosure composed of Compound 1 are injected into a knee joint for the treatment of OA.
Surgical Procedures
In some embodiments, the articles of the disclosure are used in conjunction with a surgical procedure. For example, an article of the disclosure can be implanted at a surgical site to reduce the risk of inflammation treated by the surgical procedure, or can be used as an adjunctive to reduce the risk of infection.
The following examples are put forth to provide those of ordinary skill in the art with a description of how the compositions and methods described herein may be used, made, and evaluated, and are intended to be purely exemplary of the disclosure and are not intended to limit the scope of what the inventors regard as their disclosure.
Dexamethasone (1 mol equivalent) was suspended in dichloromethane on an ice bath and triethylamine (2 mol equivalent) and triethylene glycol bis(chloroformate) (0.6 mol equivalent) were added to the mixture. The ice bath was allowed to warm to room temperature and the reaction was stirred overnight. The solvent was removed and the solid residue was purified by column chromatography. Product was recrystallized twice from acetonitrile to give Compound 1 (
A PXRD diffractogram was recorded using a Bruker D8 Discover with Davinci.Design diffractometer. The X-ray was generated using a cobalt sealed tube source (λ=1.79026 Å) with a voltage of 35 kV and a current of 45 mA. A Vantec 500 (MiKroGap Technology) area detector was used with 6 frames at 600s per frame at a distance of 20.0 cm from the sample. Raw data was integrated using Diffrac.Eva (version 4.2.1) and displayed in Topas software (Version 4.2; Bruker-AXS). The PXRD diffractogram of solid crystalline Form III of Compound 1 is shown
Compound 1: HPLC (mobile phase: H2O/TFA and MeCN/TFA) 31.7 min; Elemental analysis: Anal. Calcd for C62H68F2O16: C, 63.27; H, 6.94; N, 0.00; CI, 0.00 Found: C, 62.62; H, 6.84; N, <0.50; CI<100 ppm. 1H NMR (400 MHz, DMSO-d6) δ (ppm) 0.80 (d, J=7 Hz, 6H, 2×C16 α-CH3); 0.90 (s, 6H, 2×C18-CH3); 1.08 (m, 2H, 2×C16-H); 1.35 (m, 2H, 2×C14-H); 1.49 (s, 6H, 2×C19-CH2); 1.54 (q, J=13 Hz, 2H, 2×C13-H); 1.64 (q, J=11 Hz, 2H, 2×C15-CH2); 1.77 (m, 2H, 2×C15-CH2); 2.15 (m, 4H, 2×C6-CH2); 2.32 (m, 4H, 2×C7-CH2); 2.62 (m, 2H, 2×C12-CH2); 2.89 (m, 2H, 2×C12-CH2); 3.57 (s, 4H, 2×TEG OCH2); 3.65 (m, 4H, 2×TEG OCH2); 4.15 (m, 2H, 2×OCH); 4.22 (m, 4H, 2×TEG OCH2); 4.79 (d, 2H, AB, J=18.5 Hz, 2H, C21-CH2O—); 5.09 (d, 2H, AB, J=18.5 Hz, 2H, C21-CH2O—); 5.18 (s, 2H, C17-OH); 5.40 (d, 2H, J=4.5 Hz, C11-0H); 6.01 (d, 2H, J=1.9 Hz, 2×alkene C4-CH); 6.23 (dd, 2H, J=10.1 and 1.9 Hz, CH, 2×alkene C2-CH); 7.29 (d, 2H, C1-CH 2×alkene CH, 10.1 Hz, 2H). MS (ESI+) m/z: [M+H]+ Calcd for C52H69F2O16 987.46; Found 987.46.
Compound 1 was formed into pellets in the glassy state by heat molding (
Heat-molded pellets from Compound 1 (˜1 mm×1 mm) were then placed in 20 mL glass vials and 2 mL of release buffer (either 100% phosphate buffered saline (PBS), 1% fetal bovine serum (FBS) in PBS, or 100% FBS) was added. Samples were incubated at 37° C. on a shaker rotating at 115 rpm. After 1 day, 3 days, 7 days, and subsequently in alternating 3 and 4 day intervals (i.e., 1, 3, 7, 10, 14 days etc.), release buffer was sampled directly (PBS) or syringe filtered, proteins were precipitated with acetonitrile, and drug release products were extracted. The samples were analyzed by high performance liquid chromatography (HPLC) to quantify drug products. Cumulative drug release was calculated and plotted as a percentage of the total drug in each pellet released over time (
PXRD diffractograms generated for Examples 2 through 9 used a Copper X-ray source, different from the Cobolt X-ray source used in Example 1. There were two machines used to collect the PXRD diffractograms:
A PXRD diffractogram of solid crystalline Form I of Compound 1 is shown
Crystals of Form I were prepared by magnetically stirring a suspension of Compound 1 (11 g) in Acetonitrile (110 ml) and heating to afford a solution. The solution was cooled to room temperature and stirred for 16 hours. A white solid was filtered and dried (˜54% yield, m.p. 157.1-161.3° C.).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form II of Compound 1 is shown
Crystals of Form II were prepared by magnetically stirring suspension of Compound 1 (30.4 g) in Acetonitrile (455 ml) and heating to 70° C. to afford a solution. The solution was cooled to room temperature and left for couple of days. A white solid was filtered and dried. Recrystallization was repeated at the same conditions (˜77% yield, m.p. 164.2-167.7° C.).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form III of Compound 1 is shown
The PXRD diffractogram in Example 1 was also Form III but was captured using the cobalt X-ray source instead of the copper X-ray source as used in this example. As a result of the different X-ray sources, the 2θ values differ despite being the same form (Form III).
Crystals of Form III were prepared by forming a suspension of Compound 1 (6.83 g) in Acetonitrile (683 ml). The solution was heated to 40° C. with sonication for 30 min to afford a fine suspension which was filtered through a Whatman 40 filter paper to afford a clear yellow solution. This solution was placed in the freezer (−20° C.) and left for 4 h. A white solid (4.66 g) was collected by filtration and suspended in Acetonitrile (466 ml), heated to 40° C. with sonication for 30 min to afford a fine suspension, and filtered through a Whatman 40 filter paper to afford a clear light yellow solution. This solution was placed in the freezer (−20° C.) and left for 4 h. A white solid (4.16 g) was filtered and dried. (˜61% yield, m.p. 172° C.).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form IV of Compound 1 is shown
Crystals of Form IV were prepared by magnetically stirring a suspension of compound 1 (4 g) in 1,4-Dioxane (30 ml) and heating to 40° C. to afford a solution. The solution was cooled to room temperature. A white solid was filtered and vacuum dried at 50° C. (˜90% yield, m.p. 223.2-226.4° C. (decomp.)).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form V of Compound 1 is shown
Crystals of Form V were prepared by magnetically stirring a suspension of Compound 1 (19.6 mg) in 1,4-Dioxane (1.6 ml), heating to 60° C. for approximately 4 hours, cooling to 20° C. at 0.02° C./min rate, and storing at 5° C. for a few days. A white solid was isolated (m.p. 203.4-210.1° C.).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form VI of Compound 1 is shown
Crystals of Form VI were prepared by magnetically stirring a suspension of Compound 1 (1.12 g) in Acetonitrile-Water 10% v/v (18 ml) and heating to 60° C. for approximately 1 hour. An additional portion of Acetonitrile-Water 10% v/v (6 ml) was added to afford a clear solution. The solution was filtered while hot to remove particles not dissolved. Water (16.5 ml) was added to the solution dropwise. Solution was removed from the heating and was magnetically stirred for 3 hours at room temperature. A white solid was filtered (˜80% yield, m.p. 148.7-155.3° C.).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form VII of Compound 1 is shown
Crystals of Form VII were prepared by magnetically stirring a suspension of Compound 1 (160 mg) in Acetonitrile (2.3 ml) and heating to 60° C. for approximately 1.5 hours. An additional portion of Acetonitrile (0.75 ml) was added to afford a clear solution. Water (5.25 ml) was added to the solution dropwise. Solution was removed from the heating and was magnetically stirred for 3 hours at room temperature. A white solid was filtered (˜80% yield, m.p. 150.5-154.7° C.).
PXRD diffractograms were recorded as described in Example 2. A PXRD diffractogram of solid crystalline Form VIII of Compound 1 is shown
Crystals of Form VIII were prepared by magnetically stirring a suspension of Compound 1 (9 mg) in tetralin (800 μL) and heating at 50° C. for 1 hour. A portion of suspension (250 μL) was filtered and 400 μL heptane was added to the filtrate. A white solid was obtained after removal of the solvent.
Alternatively crystals of Form VIII were prepared by magnetically stirring a suspension of Compound 1 (9 mg) in 2-Methyl-2-Propanol (800 μL) and heating at 50° C. for 1 hour. A portion of suspension (250 μL) was filtered and 400 μL heptane was added to the filtrate. A white solid was obtained after removal of the solvent.
Form I/II (mixture) and Form IV of Compound 1 were formed from acetonitrile and ethanol respectively. The crystalline powders were suspended in phosphate buffered saline (PBS) with 50% fetal bovine serum (FBS) and drug release from the different forms was quantified by HPLC over time (see
Form I/II (mixture) has a melting point of −160-165° C. as observed by the differential scanning calorimetry (DSC) curve shown in
Form IV was the most thermodynamically stable polymorph observed, and most other polymorphs were observed to change into Form IV over time, or upon heating slowly. For example, stability testing of Forms VIII and amorphous forms showed conversion to Form IV by PXRD after 14 days at room temperature and/or cooling at 0° C. for 14 days. Finally, Form IV was not seen to convert into any other polymorphs under the conditions tested. Thus, Form IV in solid form has the advantage of longer-term shelf life without interconversion into another crystalline form.
Form II was also observed to possess high thermodynamic stability and was not observed to convert to Form IV under the conditions tested. Because Form II possesses a low melting point, it is a crystal form with high stability that can also be used for high temperature processing into articles of the invention.
The solubility of Form II and Form IV were measured in in 90% acetonitrile-10% water as a function of temperature (see
Form IV was also observed to exhibit significantly lower solubility (ca. 10-fold lower) in organic solvents (e.g., acetonitrile, ethanol, tetrahydrofuran, 2-methyl tetrahydrofuran, isobutyl acetate, acetone, butyl acetate, ethyl acetate, isopropyl acetate and methanol) than Form II. This observation has implications for coating applications as making high concentration coating solutions (e.g., for coating a surface by dip coating or spray coating a solution of Compound 1 onto the surface) will be much more practical from Form II than from Form IV.
This application claims the benefit of U.S. Provisional Ser. No. 62/883,170, filed Aug. 6, 2019, and PCT application No. PCT/CA2019/050136, filed Feb. 1, 2019, each of which is incorporated herein in its entirety.
Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the disclosure. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CA2020/050117 | 1/31/2020 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62883170 | Aug 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/CA2018/050136 | Feb 2019 | US |
| Child | 17426779 | US |
